Académique Documents
Professionnel Documents
Culture Documents
LABETALOL
Pharmacokinetics
Metabolism of labetalol is by
conjugation of glucuronic acid, with
5% of the drug recovered unchanged
in the urine.
Cardiovascular Effects
Administration of labetalol (0.1 to 0.5
mg/kg IV) lowers systemic blood
pressure by decreasing systemic
vascular resistance (1-blockade),
whereas reflex tachycardia triggered
by vasodilation is attenuated by
simultaneous -blockade. Cardiac
output remains unchanged.
Side Effects
Orthostatic hypotension is the most
common side effect of labetalol
therapy. Because fluid retention
commonly occurs in patients treated
chronically with labetalol, this drug is
combined with a diuretic during
prolonged therapy.
-BLOCKER
Penghambat reseptor memiliki beberapa
derajat selektifitas. Penghambat yang
lebih selektif terhadap reseptor 1
memiliki pengaruh yang lebih sedikit pada
bronkopulmonar dan vaskular.
Secara teoritis, penghambat 1 selektif
memiliki efek inhibisi yang rendah pada
reseptor 2, dan karena itu
penggunaannya lebih disukai untuk pasien
dengan penyakit paru obstruktif kronik
atau penyakit vaskular perifer.